Lilly attracts Boehringer Ingelheim to diabetes venture
This article was originally published in Scrip
Lilly and Boehringer Ingelheim have linked up on a broad venture to co-develop and co-commercialise four diabetes drugs in mid- and late-stage development, with opt-in rights for a fifth molecule, as Lilly in particular seeks to rejuvenate its diabetes business following a setback with its own pipeline late last year. Indeed, diabetes accounts for about 17% of Lilly sales – all its products are currently injectables - but in recent years the company has been losing ground in the marketplace to competitors such as NovoNordisk.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.